These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 11830531

  • 1. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G.
    Cancer Res; 2002 Feb 01; 62(3):764-72. PubMed ID: 11830531
    [Abstract] [Full Text] [Related]

  • 2. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
    Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van Beusechem VW.
    Cancer Res; 2004 Aug 15; 64(16):5753-9. PubMed ID: 15313916
    [Abstract] [Full Text] [Related]

  • 3. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.
    Cancer Res; 2001 Sep 01; 61(17):6428-36. PubMed ID: 11522637
    [Abstract] [Full Text] [Related]

  • 4. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
    Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D.
    Cancer Res; 2000 Nov 15; 60(22):6359-66. PubMed ID: 11103798
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
    Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB.
    Clin Cancer Res; 2000 Mar 15; 6(3):798-806. PubMed ID: 10741699
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
    Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D.
    Gene Ther; 2000 Nov 15; 7(22):1925-9. PubMed ID: 11127580
    [Abstract] [Full Text] [Related]

  • 8. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.
    Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS.
    Cancer Res; 1999 Sep 01; 59(17):4369-74. PubMed ID: 10485485
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
    Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D.
    Gene Ther; 2001 Feb 01; 8(4):308-15. PubMed ID: 11313805
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J, Cho JY, Kim JH, Jung KC, Yun CO.
    Cancer Gene Ther; 2002 Sep 01; 9(9):725-36. PubMed ID: 12189522
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW.
    Cancer Res; 2006 Oct 01; 66(19):9736-43. PubMed ID: 17018633
    [Abstract] [Full Text] [Related]

  • 13. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
    You L, Yang CT, Jablons DM.
    Cancer Res; 2000 Feb 15; 60(4):1009-13. PubMed ID: 10706117
    [Abstract] [Full Text] [Related]

  • 14. Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and DeltaE1B adenovirus replication in human cells.
    Steegenga WT, Riteco N, Bos JL.
    Oncogene; 1999 Sep 09; 18(36):5032-43. PubMed ID: 10490840
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adenovirus lacking the 19-kDa and 55-kDa E1B genes exerts a marked cytotoxic effect in human malignant cells.
    Duque PM, Alonso C, Sánchez-Prieto R, Lleonart M, Martínez C, de Buitrago GG, Cano A, Quintanilla M, Ramon y Cajal S.
    Cancer Gene Ther; 1999 Sep 09; 6(6):554-63. PubMed ID: 10608352
    [Abstract] [Full Text] [Related]

  • 17. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.
    Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH.
    Cancer Res; 2000 Mar 01; 60(5):1193-6. PubMed ID: 10728673
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.